Xenetic Biosciences Inc., of Framingham, Mass., said on June 25 it effected a 1-for-12 reverse stock split of its issued and outstanding common shares. The company's common stock continues to trade on Nasdaq on a split-adjusted basis under the ticker XBIO, closing Wednesday at $8.30 for a loss of 86 cents.